iSAM Funds UK Ltd Acquires Shares of 8,433 STERIS plc $STE

iSAM Funds UK Ltd bought a new stake in STERIS plc (NYSE:STE) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 8,433 shares of the medical equipment provider’s stock, valued at approximately $2,026,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Spurstone Advisory Services LLC purchased a new stake in STERIS in the second quarter valued at approximately $29,000. Geneos Wealth Management Inc. increased its holdings in shares of STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares during the period. Zions Bancorporation National Association UT purchased a new stake in STERIS in the 1st quarter valued at $37,000. Loomis Sayles & Co. L P acquired a new stake in STERIS during the 2nd quarter worth $54,000. Finally, Generali Investments Management Co LLC purchased a new position in STERIS during the 2nd quarter worth $56,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Stock Down 0.8%

STE stock opened at $261.29 on Tuesday. The stock has a market capitalization of $25.65 billion, a PE ratio of 37.54 and a beta of 1.01. The company has a fifty day moving average of $250.32 and a 200-day moving average of $243.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. STERIS plc has a one year low of $200.98 and a one year high of $268.60.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. STERIS had a net margin of 12.07% and a return on equity of 14.43%. During the same period in the previous year, the business posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, analysts expect that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS’s dividend payout ratio is 36.21%.

Insiders Place Their Bets

In other STERIS news, VP John Adam Zangerle sold 15,000 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the completion of the transaction, the vice president owned 33,669 shares in the company, valued at approximately $8,926,998.66. This represents a 30.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Renato Tamaro sold 5,036 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total value of $1,297,021.80. Following the completion of the sale, the vice president directly owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. This trade represents a 46.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 25,203 shares of company stock valued at $6,624,667 over the last 90 days. 1.07% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

STE has been the subject of a number of research reports. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.